A potential problem for Pfizer Lipitor brand and their R&D activities‚ as well as their business in general‚ is the fact that Lipitor will soon lose its patent protection. The problem is that they do not have any suitable replacements for the revenue that will soon be lost due to the emergence of generic drugs following a branded drugs loss of patent protection. Their main source of revenue‚ Lipitor (sales of $10 billion last year)‚ will lose its patent protection in 2010. 4 Alternative/Suggested
Premium Marketing Competition Brand
Based on ”Gone‚” BusinessWeek‚ December 20‚ 2004‚ 76-82. CASE 1 PFIZER‚ INC. OVERVIEW In the 1990’s Pfizer experienced tremendous growth and strong financial performance. The success of its blockbuster drugs and newly released prescription drugs with a vast consumer market‚ allowed Pfizer to increase its customer base and raises its prices. Lately growth has slipped to just 2% a year. Pfizer’s pipeline of drugs has failed to provide a recent blockbuster. If no big drug releases occur
Premium Pharmacology Marketing Pharmaceutical drug
Marketing Analysis Paper Pfizer Inc. is a large pharmaceutical company that engages in the discovery of new technologies‚ the manufacture of prescription and "over the counter" (OTC) medicines‚ as well as the marketing of such products. It operates in three distinct segments that include Human Health‚ Consumer Healthcare‚ and Animal Health. For fiscal year 2004‚ the company generated approximately $53 billion in revenue that contributed to over $11 billion in net income. (Pfizer‚ 2004) The Cow and
Premium Marketing Medicine Health
on their big money products runs out. Gilmartin found it an ideal time to invest in R&D while many of the other companies were investing in mergers which he saw as only a short term gain Pfizer Company Pfizer is a stakeholder in the Merck company simply because Pfizer is their major competitor. Pfizer is
Premium Pharmacology Finance Management occupations
Msc in Economics and Business Administration Master Thesis MSc in Finance Valuation of Pfizer Inc. and analysis of new drug development project using a real option approach. Author: Valdis Cvetkovs Supervisor: Peter Lochte Jorgensen April 2011 Aarhus Abstract This thesis investigates the world’s largest pharmaceutical company Pfizer Inc. from strategic and financial viewpoint in order to determine companies’ fair market value. The external analysis researches industry and global economic situation
Premium Balance sheet Cash flow Generally Accepted Accounting Principles
Launch Plan Pfizer Inc is the largest research based biomedical and pharmaceutical company in the world. Headquartered in New York‚ Pfizer has major research and development locations in England and the United States. Since its inception in 1849‚ the organization has remained dedicated to discovering and developing new and better ways to prevent and treat disease‚ while helping to improve health and well being for people around the world. In November‚ the Pfizer product Lipitor that
Premium Marketing People's Republic of China Pharmaceutical industry
a change. The more consumers hear about big cases‚ like that of Pfizer‚ the more they can begin to question. The purpose of this paper is to talk about the awareness
Premium Pharmacology Medicine Food and Drug Administration
Pest Analysis on Pfizer Pfizer Incorporated (NYSE: PFE) is a pharmaceutical company‚ ranking number one in sales in the world. The company is based in New York City‚ with its research headquarters in Groton‚ Connecticut. It produces Lipitor (atorvastatin‚ used to lower blood cholesterol); the neuropathic pain/fibromyalgia drug Lyrica (pregabalin); the oral antifungal medication Diflucan (fluconazole)‚ the antibiotic Zithromax (azithromycin)‚ Viagra (sildenafil) for erectile dysfunction‚ and the
Premium
reach required economies of scale. Bigger companies can allow investments in more research and development projects that diversify their future drugs portfolio and make them much more stable. Pfizer: Pfizer is one of the world’s leading research-based biomedical and pharmaceutical companies. Although Pfizer is in the intensive competitive pharmaceutical industry and there
Premium Pharmaceutical industry Pharmacology Generic drug
Finance‚ we reviewed the Cost of Capital video. This video provided information on Pfizer‚ a researched based pharmaceutical company that makes products to help face health care challenges. Our goal is to highlight the cost of capital as described by Amit Singh regarding Pfizer ’s funds in terms of debt and equity along with using the Capital Asset Pricing Model (CAPM). The Weight Average Cost of Capital (WACC) and how Pfizer uses this method will be reviewed. Additionally‚ each phase of developing and
Premium Finance Weighted average cost of capital Corporate finance